Get the Stockscreener App
95.49
6.55%
-6.695
After Hours:
95.49
Mirum Pharmaceuticals Inc stock is traded at $95.49, with a volume of 1.01M.
It is down -6.55% in the last 24 hours and down -2.51% over the past month.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.
See More
Previous Close:
$102.19
Open:
$102.19
24h Volume:
1.01M
Relative Volume:
1.04
Market Cap:
$5.82B
Revenue:
$521.31M
Net Income/Loss:
$-23.36M
P/E Ratio:
-199.73
EPS:
-0.4781
Net Cash Flow:
$54.87M
1W Performance:
-10.06%
1M Performance:
-2.51%
6M Performance:
+32.28%
1Y Performance:
+112.15%
1-Day Range:
$94.31
$102.56
1-Week Range:
$94.31
$114.99
52-Week Range:
$42.89
$114.99
Mirum Pharmaceuticals Inc Stock (MIRM) Company Profile
Name
Mirum Pharmaceuticals Inc
Sector
Industry
Phone
650-667-4085
Address
989 EAST HILLSDALE BOULEVARD, SUITE 300, FOSTER CITY
Compare MIRM vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MIRM
Mirum Pharmaceuticals Inc
|
95.49 | 6.23B | 521.31M | -23.36M | 54.87M | -0.4781 |
VRTX
Vertex Pharmaceuticals Inc
|
436.58 | 110.90B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
629.68 | 73.20B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
776.26 | 49.71B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
286.27 | 38.32B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
144.37 | 30.97B | 742.00K | -1.37B | -1.07B | -7.0731 |
Mirum Pharmaceuticals Inc Stock (MIRM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-18-26 | Initiated | RBC Capital Mkts | Outperform |
| Sep-24-25 | Initiated | TD Cowen | Buy |
| Aug-11-25 | Resumed | Stifel | Buy |
| May-19-25 | Resumed | H.C. Wainwright | Buy |
| Apr-17-24 | Initiated | Stifel | Buy |
| Dec-18-23 | Reiterated | H.C. Wainwright | Buy |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Nov-13-23 | Initiated | Morgan Stanley | Overweight |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-17-23 | Resumed | Evercore ISI | Outperform |
| Sep-20-23 | Initiated | JMP Securities | Mkt Outperform |
| Sep-01-22 | Initiated | Citigroup | Buy |
| Sep-20-21 | Initiated | JP Morgan | Overweight |
| Aug-07-20 | Upgrade | Raymond James | Outperform → Strong Buy |
| Aug-03-20 | Initiated | H.C. Wainwright | Buy |
| Jul-31-20 | Initiated | Piper Sandler | Overweight |
| Jun-25-20 | Initiated | Robert W. Baird | Outperform |
| Aug-12-19 | Initiated | Citigroup | Buy |
| Aug-12-19 | Initiated | Evercore ISI | Outperform |
| Aug-12-19 | Initiated | Guggenheim | Buy |
| Aug-12-19 | Initiated | ROTH Capital | Buy |
| Aug-12-19 | Initiated | Raymond James | Outperform |
View All
Mirum Pharmaceuticals Inc Stock (MIRM) Latest News
Mirum Pharmaceuticals director Saira Ramasastry sells $218,940 stock - Investing.com
[Form 4] Mirum Pharmaceuticals, Inc. Insider Trading Activity - Stock Titan
Mirum Pharmaceuticals Issues $690 Million Convertible Senior Notes - TipRanks
Mirum Pharmaceuticals (NASDAQ: MIRM) sells $600M 2032 converts, to refinance 2029 notes - Stock Titan
Mirum Pharmaceuticals (MIRM) price target increased by 16.75% to 149.29 - MSN
Mirum Pharmaceuticals prices $600M senior notes - MSN
2,000-share sale via option exercise — MIRM (NASDAQ: MIRM) Form 144 - Stock Titan
Mirum Pharmaceuticals, Inc.common stock (NQ: MIRM - The Chronicle-Journal
Mirum's Q1 earnings & revenues beat estimates, 2026 view raised - MSN
Mirum Pharmaceuticals (MIRM) moves 5.1% higher: Will this strength last? - MSN
Latham & Watkins Advises on Mirum Pharmaceuticals’ US$600 Million Convertible Senior Notes Offering - Latham & Watkins LLP
Mirum Pharmaceuticals reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
(MIRM) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Mirum Pharmaceuticals stock (US60471A1034): Hits all-time high amid $600M debt deal - AD HOC NEWS
Mirum Pharmaceuticals stock hits all-time high at 112.47 USD By Investing.com - Investing.com Nigeria
Mirum Pharmaceuticals stock hits all-time high at 112.47 USD - Investing.com
Mirum Pharmaceuticals Prices $600 Million Private Debt Offering - Moomoo
Mirum Pharmaceuticals Prices $600.0 Million Convertible Senior Notes Offering; Refinances a Portion of 2029 Convertible Notes - BioSpace
Mirum plans $600 million convertible notes offering due 2032 By Investing.com - Investing.com South Africa
Mirum prices $600m convertible notes offering due 2032 By Investing.com - Investing.com South Africa
Mirum prices $600m convertible notes offering due 2032 - Investing.com
Mirum Pharmaceuticals Prices $600.0 Million Convertible Senior Notes Offering - TradingView
Mirum raises $600M in 0% convertible notes, starts 2029 debt swap - Stock Titan
Mirum pharmaceuticals announces proposed convertible senior notes offering - marketscreener.com
Mirum Pharmaceuticals Announces Proposed Convertible Senior Notes Offering - TradingView
Mirum Pharmaceuticals shares fall 2% after announcing $600 million bond offering - Investing.com Canada
Mirum plans $600 million convertible notes offering due 2032 - Investing.com
Mirum Pharmaceuticals Announces Private Placement of Convertible Senior Notes to Qualified Institutional Buyers - geneonline.com
User | smdailypress.comMirum Pharmaceuticals Announces Proposed Convertible Senior Notes Offering - FinancialContent
Mirum Pharmaceuticals: A Rare Disease Platform Becoming Bigger Than Its First Franchise - Seeking Alpha
Mirum Pharmaceuticals to Participate in Upcoming May 2026 Investor Conferences - BioSpace
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences - The Chronicle-Journal
Mirum Pharmaceuticals, Inc. $MIRM Shares Sold by State of New Jersey Common Pension Fund D - MarketBeat
Mirum Pharmaceuticals, Inc. (MIRM) reports Q1 loss, beats revenue estimates - MSN
Number of shareholders of Mirum Pharmaceuticals, Inc. – TRADEGATE:08D - TradingView
Nan Fung Trinity HK Ltd. Increases Stock Holdings in Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat
Mirum Pharmaceuticals rally reflects confidence in late-stage liver disease assets - msn.com
MIRM Stock Clocks Best Day In 4.5 Months On Liver Disease Trial Data: Retail Eyes Buyout At A Premium - Stocktwits
Mirum Pharmaceuticals (NASDAQ:MIRM) Stock Rating Lowered by Wall Street Zen - MarketBeat
MIRM stock clocks best day in 4.5 months on liver disease trial data: Retail eyes buyout at a premium - MSN
H.C. Wainwright Maintains Mirum Pharmaceuticals(MIRM.US) With Buy Rating, Maintains Target Price $185 - Moomoo
Primary goal achieved in Mirum’s Phase IIb trial of volixibat - MSN
Mirum raises 2026 net product sales outlook to $660M-$680M as it targets year-end zilurgisertib launch - MSN
Mirum Pharmaceuticals (MIRM) Is Up 16.9% After Volixibat Phase 2b PSC Itch Data And Big Q1 LossHas The Bull Case Changed? - Yahoo Finance
RBC Capital Adjusts Mirum Pharmaceuticals Price Target to $142 From $128, Maintains Outperform Rating - Moomoo
Mirum's Q1 Earnings & Revenues Beat Estimates, 2026 View Raised - Yahoo Finance
Mirum Pharmaceuticals Inc Stock (MIRM) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):